SCHEDULE 13G/A: Janus Henderson Group Increases Stake in Benitec Biopharma to 11.4%
Beneficial Ownership Report
Janus Henderson Group plc and its affiliates have reported an increased beneficial ownership stake of 11.4% in Benitec Biopharma Inc. common stock as of March 31, 2025.
Summary
- Janus Henderson Group plc, a Jersey-based parent holding company and investment adviser, along with its indirect subsidiaries, has filed an Amendment No. 7 to Schedule 13G regarding its beneficial ownership in Benitec Biopharma Inc.
- As of March 31, 2025, Janus Henderson Group plc beneficially owns an aggregate of 2,918,950 shares of Benitec Biopharma Inc. common stock, representing 11.4% of the class.
- Janus Henderson Group plc holds shared voting and dispositive power over all 2,918,950 shares.
- Janus Henderson Biotech Innovation Master Fund Ltd, a Massachusetts-based investment company and an indirect subsidiary of Janus Henderson Group plc, beneficially owns 2,193,481 shares, representing 8.6% of the class.
- The filing states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual report of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
This filing reflects a significant passive investment by a major financial institution in a biotechnology company. Such filings are routine disclosures of ownership stakes and do not inherently indicate strategic shifts within the broader biotechnology or investment management industries, beyond the specific investment decision by Janus Henderson.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional ownership stake by Janus Henderson Group plc may be viewed positively by other investors, potentially signaling confidence in Benitec Biopharma Inc. or its long-term prospects. It also provides transparency regarding the ownership structure.
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Date of execution of Power of Attorney by Janus Henderson Group plc. |
| 2025-03-31 | Date of event which requires filing of this statement, representing the snapshot date for beneficial ownership. |
| 2025-05-14 | Date of filing of the Schedule 13G Amendment No. 7. |
Keywords
Benitec Biopharma Inc., Janus Henderson Group plc, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.